Mountaineer nct03043313
Nettet2. feb. 2024 · Data from the phase 2 MOUNTAINEER (NCT03043313) trial supported the approval, which showed that at a median follow-up of 20.7 months, the combination elicited an overall response rate (ORR) of 38% ... NettetMOUNTAINEER is a multicenter open-label single-arm phase II trial. Pts with RAS WT mCRC had HER2 amplification/overexpression by NGS, FISH, or IHC (3+ or 2+ and amplified by FISH). Prior treatment with 5FU, oxaliplatin, irinotecan, and an anti-VEGF antibody was required. Prior anti-HER2 therapy was excluded.
Mountaineer nct03043313
Did you know?
NettetMOUNTAINEER is an open-label, pivotal phase II study that initially consisted of a single cohort of up to 45 pts (Cohort A) treated with TUC (300 mg BID) and TRAS (8 mg/kg IV followed by 6 mg/kg IV every 3 weeks). Nettet20. jan. 2024 · Based on these results, the trial was expanded to enable better estimation of ORR and safety. Methods: MOUNTAINEER (NCT03043313) is an open-label, pivotal phase 2 trial that initially consisted of a single cohort of up to 45 pts (Cohort A) treated with TUC (300 mg BID) and TRAS (8 mg/kg IV followed by 6 mg/kg IV every 3 weeks).
Nettet12. apr. 2024 · 此次Tukysa获得优先审批是基于代号为MOUNTAINEER的 2 期试验 (NCT03043313) 的临床结果。 值得一提的是，这是HER+结直肠癌获批的头款靶向治疗方案，对于行业以及广大患者都具有重要意义。 Nettet23. mai 2024 · Roger Dansey, MD. The combination of tucatinib (Tukysa) and trastuzumab (Herceptin) produced promising response rates in patients with previously treated HER2 -positive metastatic colorectal ...
NettetThe MOUNTAINEER trial (NCT03043313) was initiated to evaluate the efficacy and safety of the investigational combination of tucatinib with trastuzumab in patients with HER2+ mCRC. Here we present results from the primary analysis of MOUNTAINEER. Methods: MOUNTAINEER is a multi-center, open-label, randomised, phase 2 trial conducted in … NettetMOUNTAINEER (NCT03043313) is evaluating safety and efficacy of TUC and trastuzumab (Tras) in pts w/ tx refractory RAS wild-type, HER2+ mCRC; preliminary …
Nettet2. jul. 2024 · Patients with previously treated metastatic HER2-positive colorectal cancer (mCRC) experienced clinically meaningful and durable responses to treatment with …
NettetMOUNTAINEER: Tucatinib plus trastuzumab demonstrates good efficacy for the treatment of HER2-positive metastatic colorectal cancer. In the U.S., colorectal cancer (CRC) is the third leading cause of cancer-related deaths and is expected to lead to approximately 52,580 deaths in 2024. Human epidermal growth factor receptor 2 (HER2) is … taste holiday magic sweepstakesNettet20. jan. 2024 · Request PDF MOUNTAINEER: ... (NCT03043313). [88] The efficacy of neratinib in HER2 amplified or mutated disease and in anti-EGFR resistant disease is under study in a phase II trial (NCT03457896). taste holdings limited afsNettetTucatinib is a highly selective, HER2-directed, tyrosine kinase inhibitor. The MOUNTAINEER trial (NCT03043313) was initiated to evaluate the efficacy and safety of the investigational combination of tucatinib with trastuzumab in patients with HER2+ mCRC. Here we present results from the primary analysis of MOUNTAINEER. Methods taste hk edinburghNettet24. jan. 2024 · MOUNTAINEER (NCT03043313) evaluated the safety and efficacy of TUC and trastuzumab (Tras) in pts w/ tx refractory RAS wild-type, HER2+ mCRC. Results … taste hampsteadNettet27. sep. 2024 · John Strickler, MD, Duke Cancer Center, Durham, NC, discusses the initial results of the MOUNTAINEER trial (NCT03043313). This Phase II trial studies how the HER2 inhibitor tucatinib works in combination with trastuzumab in treating … taste holdings limitedNettet16. jun. 2024 · In the MOUNTAINEER trial (NCT03043313) in HER2-amplified, metastatic colorectal cancer patients, an ORR of 52% was achieved (12/23 evaluable patients; 26 April 2024 data cut-off date). The primary efficacy endpoint was considered to be met as the ORR was above the pre-specified cutoff of 40%. taste hobartNettet10. jul. 2024 · Data from the phase 2 MOUNTAINEER trial (NCT03043313) showed that patients with previously treated metastatic HER2-positive colorectal cancer (mCRC) had a sustained response to treatment with dual-HER2 inhibitors tucatinib (Tukysa) plus trastuzumab (Herceptin). 1. Findings, which were presented at the 2024 ESMO World … co jest po baroku